Status:
ACTIVE_NOT_RECRUITING
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem
Lead Sponsor:
MicroPort Orthopedics Inc.
Conditions:
Joint Disease
Eligibility:
All Genders
21+ years
Brief Summary
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European U...
Eligibility Criteria
Inclusion
- Newly or previously implanted subjects must meet all the following inclusion Criteria:
- Has undergone primary Total Hip Arthroscopy for any of the following:
- Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;lnflammatory degenerative joint disease such as rheumatoid arthritis; or
- Correction of functional deformity;
- Subject is implanted with the PROFEMUR® Preserve Femoral Stem(s) and cobalt-chromium Modular Neck;
- Subject is willing and able to complete required study visits or assessments through the 10 year postoperative follow-up schedule;
- Subject is implanted with WMT or MPO head, cup and liner.
- Newly or previously implanted bilateral subjects can have both Total Hip Arthroscopy enrolled in the study provided: 1) the specified PROFEMUR® Preserve Femoral Stems and cobalt-chromium Modular Necks were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second Total Hip Arthroscopy.
- Previously implanted subjects who had undergone revision of any Total Hip Arthroscopy component including the PROFEMUR® Preserve Femoral Stem(s) or, cobalt-chromium Modular Neck will also be eligible to be considered for this study.
- Exclusion Criteria:
- Subjects will be excluded if they meet any of the following criteria:
- Subjects implanted with non-MicroPort or Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners);
- Subjects implanted with a PROFEMUR® Preserve stem assembled to a Titanium Modular Neck;
- Subjects skeletally immature (less than 21 years of age) at time of primary Total Hip Arthroscopy surgery;
- Subjects have or had an overt infection at the time of implantation;
- Subjects have or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation;
- Subjects have or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at time of implantation;
- Subjects have or had inadequate neuromuscular status (e.g., prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable;
- Subject has neuropathic joints;
- Subject has hepatitis or HIV infection;
- Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing;
- Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol;
- Subjects unwilling or unable to sign the Informed Consent document;
- Subjects with documented substance abuse issues;
- Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study;
- Subjects who are incarcerated or have pending incarceration.
Exclusion
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2032
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT03865667
Start Date
January 15 2019
End Date
January 1 2032
Last Update
April 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Manel Ribas
Barcelona, Spain, 08028